Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Romero sues supplement firms

This article was originally published in The Tan Sheet

Executive Summary

Phillies reliever J.C. Romero sues supplement makers Ergopharm and Proviant Technologies, allegedly the firms failed to list all ingredients on the label of 6-OXO Extreme, a testosterone boosting supplement. In the suit filed April 27 in the Superior Court in Camden, N.J., Romero alleges the supplement caused him to test positive for substances banned by Major League Baseball, resulting in his suspension during the 2008 World Series and for the first 50 games of this season. He seeks compensatory and punitive damages. Proviant Technologies disputes the allegations and told media 6-OXO Extreme warns on the label that using the product may be banned by some sports leagues or government associations. Earlier this year, supplement maker AdvoCare accused a professional swimmer of defamation after she and her coach suggested to media that its products were tainted with a prohibitied performance-enhancing substance. The athlete has filed a liability and negligent claim against Carrollton, Texas.-based AdvoCare (1"The Tan Sheet" Feb. 23, 2009, p. 6)

You may also be interested in...



AdvoCare’s Suit Aims At Athletes Falsely Blaming Supplements For Failed Tests

A high-stakes legal battle about allegedly contaminated dietary supplements could make athletes who test positive for banned substances think twice before blaming dietary supplements

Pipeline Watch: Five Approvals And 23 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102875

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel